Serum CA125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: A multicenter italian study

International Journal of Gynecological Cancer

Volumn 7, Issue 1, 1997, Pages 78-83

  Gadducci, A ^a   Landoni, F ^b   Maggino, T ^c   Sartori, E ^d   Zola, P ^e   Ferdeghini, M ^a   Parma, G ^b   Cristofani, R ^f  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

CA125; ovarian cancer; prognosis; recurrence

Indexed keywords

CA 125 ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CLINICAL TRIAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; ITALY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RELAPSE; TUMOR LOCALIZATION;

EID: 0031014390     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1997.00424.x     Document Type: Article

References (32)

1. Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991; 9: 1138-50.
2. Rubin SC, Hoskins WJ, Saigo PE, et al. Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum based chemotherapy. Gynecol Oncol 1991; 42: 137-41.
3. Marsoni S, Torri V, Valsecchi MG, et al. Prognostic factors in advanced epithelial ovarian cancer. Br J Cancer 1990; 62: 444-50.
4. Friedlander ML, Dembo AJ. Prognostic factors in ovarian cancer. Semin Oncol 1991; 18: 205-12.
5. Cruickshank DJ, Fullerton WT, Klopper A. The clinical significance of pre-operative serum CA 125 in ovarian cancer. Br J Obstet Gynaecol 1987; 94: 692-5.
6. Mobus V, Kreienberg R, Crombach G. Evaluation of CA 125 as a prognostic and predictive factor in ovarian cancer. J Tumor Marker Oncol 1988; 3: 251-8.
7. van der Burg MEL, Lammes FB, van Putten WLJ, Stoter G. Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecol Oncol 1988; 30: 307-12.
8. Sevelda P, Schemper M, Spona J. CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1989; 161: 1213-16.
9. Rustin GJS, Gennings JN, Nelstrop AE, et al. for the North Thames Cooperative Group. Use of CA-125 to predict survival of patients with ovarian carcinoma. J Clin Oncol 1989; 7: 1667-71.
10. Makar AP, Kristensen GB, Kaern J, et al. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol 1992; 79: 1002-10.
11. Gadducci A, Zola P, Landoni F, et al. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric italian study. Gynecol Oncol 1995; 58: 42-7.
12. Hawkins RE, Roberts K, Wiltshaw E, et al. The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol 1989; 96: 1395-9.
13. Hunter VJ, Daly L, Helms M, et al. The prognostic significance of CA125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol 1990; 163: 1164-7.
14. Hogberg T, Kagedal B. Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma. Acta Obstet Gynecol Scand 1990; 69: 423-9.
15. Willemse PH, Aalders JG, De Bruijn HW, et al. CA-125 in ovarian cancer; Relation between half-life, doubling time and survival. Eur J Cancer 1991; 27: 993-5.
16. Rosman M, Hayden CL, Thiel RP, et al. Prognostic indicators for poor-risk epithelial ovarian carcinoma. Cancer 1994; 74: 1323-8.
17. Fayers PM, Rustin G, Wood R, et al. On behalf of the MRC Working Party on Gynaecological Cancer. The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: An analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer. Int J Gynecol Cancer 1993; 3: 285-92.
18. Niloff JM, Knapp RC, Lavin PT, et al. The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol 1986; 155: 56-60.
19. Schilthuis MS, Aalders JG, Bouma J, et al. Serum CA125 levels in epithelial ovarian cancer: Relation with findings at second-look operations and their role in the detection of tumour recurrence. Br J Obstet Gynaecol 1987; 94: 202-7.
20. Zanaboni F, Presti M, Scarfone G, Bolis G. CA 125 reliability in predicting ovarian cancer recurrence. Tumori 1989; 75: 69-71.
21. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: A review of the literature. Hum Reprod 1989; 4: 1-12.
22. van der Burg MEL, Lammes FB, Verweij J. The role of CA 125 in the early detection of progressive disease in ovarian cancer. Ann Oncol 1990; 1: 301-2.
23. Fioretti P, Gadducci A, Ferdeghini M et al. The concomitant determination of different serum tumor markers in epithelial ovarian cancer: Relevance for monitoring the response to chemotherapy and follow-up of patients. Gynecol Oncol 1992; 44: 155-60.
24. Hogberg T, Kagedal B. Long-term follow-up of ovarian cancer with monthly determinations of serum CA 125. Gynecol Oncol 1992; 46: 191-8.
25. Rustin GJS, van der Burg MEL, Berek JS. Tumour markers Ann Oncol 1993; 4 (Suppl. 4): 71-7.
26. Makar AP, Kristensen GB, Bormer OP, Tropè CG. Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer? Gynecol Oncol 1993; 49: 3-7.
27. Perez RP, Hamilton TC, Ozols RF, Young RC. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer 1993; 71: 1571-80.
28. Vogl SE, Pagano M, Kaplan BH, et al Combination chemotherapy of advanced ovarian cancer with hexamethylmelamine, cis-platinum, and doxorubicin after failure of prior therapy. Obstet Gynecol 1980; 56: 635-40.
29. Richardson GS, Scully RE, Nikrui N, Nelson JH Jr. Common epithelial cancer of the ovary. N Engl J Med 1985; 312: 415-24.
30. Blackledge G, Lawton F, Redman C, Kelley K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and design of phase II trials. Br J Cancer 1989; 59: 650-3.
31. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-93.
32. Thigpen JT, Vance RB, Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 1993; 71: 1559-64.